• Seetha Ram Kotra Department of Biotechnology Acharya Nagarjuna University Guntur
  • Peravali B J Department of Biotechnology Bapatla Engineering College Bapatla, Guntur
  • Anmol Kumar Department of Biotechnology Acharya Nagarjuna University Guntur
  • krs Sambasiva Rao Department of Biotechnology Acharya Nagarjuna University Guntur
  • K K Pulicherla Department of Biotechnology R.V.R & J. C. College of Engineering Guntur


Every year most of the deaths were leaded by cardio and cerebrovascular disorders around the globe. The use of first or second generation thrombolytics may rise several side effects like bleeding in biological system at the time of treatment. New generation thrombolytics plays an important role in the treatment of thromboembolic disorders which leads to the death. An ideal fibrin specific plasminogen activator, staphylokinase converts a precursor, plasminogen to active enzyme, plasmin to dissolve the blood clot during thrombolytic therapy and it also capable to destroy the normal components of hemostatic system which leads to life threatening consequence and also death. Out of four different thrombolytics which are available in market like alteplase, reteplase, streptokinase and tenecteplase, streptokinase was widely used drug because of its low cost. But, to overcome the hurdles like bleeding and reocculsion efforts have been made to construct the more potent staphylokinase devoid of risk. In this review, progressive development on staphylokinase has been discussed.

Key words: Cerebrovascular disorders, thrombolytics, fibrin specific, streptokinase, staphylokinase, reocclusion.

Author Biographies

Seetha Ram Kotra, Department of Biotechnology Acharya Nagarjuna University Guntur
Department of Biotechnology Acharya Nagarjuna University Guntur
Peravali B J, Department of Biotechnology Bapatla Engineering College Bapatla, Guntur

Department of BiotechnologyBapatla Engineering College

Bapatla, Guntur
Anmol Kumar, Department of Biotechnology Acharya Nagarjuna University Guntur
Department of Biotechnology Acharya Nagarjuna University Guntur
krs Sambasiva Rao, Department of Biotechnology Acharya Nagarjuna University Guntur
Department of Biotechnology Acharya Nagarjuna University Guntur
K K Pulicherla, Department of Biotechnology R.V.R & J. C. College of Engineering Guntur
Department of Biotechnology R.V.R & J. C. College of Engineering Gunturof Biotechnology R.V.R & J. C. College of Engineering Gunturof Biotechnology R.V.R & J. C. College of Engineering Guntur


American Heart Association. Dallas Heart Disease and Stroke Statics-2009.

MacFarlane RD. Hemostasis: introduction. Br Med Bull. 1977. 33, 183 - 94.

Collen D. Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction. Circulation. 1996. 93, 85765.

Sussmann BJ and Fitch TSP. Thrombolysis with fibrinolysin in cerebral artery occlusion. JAMA. 1958. 167, 1705 – 09.

Clarke RL and Cliffton EE. The treatment of cerebrovascular thrombosis and embolism with fibrinolytic agents. Am J Cardiol. 1960. 6, 546 – 51.

Wiman B and Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem. 1997. 78, 19 – 26.

Albers GW, Clark WM, Madden KP and Hamilton SA. ATLANTIS Trial: Results for patients treated within 3 hours of stroke onset. Altephase Thrombolysis for Acute Non intervetional Therapy in Ischemic Stroke. Stroke. 2002. 33, 493 – 95.

Anmol Kumar, Pulicherla KK, Seetha Ram K and KRS Sambasiva Rao. Evolutionary trend of thrombolytics. International Journal of Bio-Science and Bio-Technology. 2010. 2, 51 – 67.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl. J Med. 1993. 329, 673 – 82.

Ouriel K. A History of thrombolytic therapy. J Endovasc Ther. 2004. 11 Suppl 2: II, 128 – 133.

Qing Huai, Andrew P Mazar, Alice Kuo, Graham C Parry, David E Shaw, Jennifer Callahan, Yongdong Li, Cai Yuan, Chuanbing Bian, Liqing Chen, Bruce Furie, Barbara C Furie, Douglas B Cines and Mingdong Huang. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006. 311, 656 – 659.

Sikri N and Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007. 34, 318 – 27.

Lakshmi V Mundada, Mary Prorok, Melanie E DeFord, Mariana Figuera, Francis J Castellino and William P Fay. Structure-function analysis of streptokinase amino terminus. J Biol Chem. 2003. 278, 24421 – 27.

Anderson JL. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent. J Am Coll Cardiol. 1987. 10, 22B – 27B

Rijken DC and Collen DC. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981. 256, 7035 – 41.

Valery V. Novokhatny, Kenneth C Ingham and Leonid V Medved. Domain structure and domain-domain interactions of recombinant tissue plasminogen activator. J Biol Chem. 1991. 266, 5191 – 5200.

Mimuro J, Kaneko M, Murakami T, Matsuda M and Sakata Y. Reversible interaction between plasminogen activators and plasminogen activator inhibitor-1. Biochim Biophys Acta. 1992. 1160, 325 – 34.

Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJ and Presta L. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem. 1991. 266, 5191 – 5201.

Topol EJ, Morriss DC and Smalling RW. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue type plasminogen activator (Activase®) in acute myocardial infarction. J Am Coll Cardiol. 1987. 9, 1205 – 13.

Genentech, Inc., information on file; September 2001

The GUSTO Angiographic Investigators. The effect of tissue plasmino activator, streptokinase, or both on coronary patency,ventricular function,and survival after acute myocardial infarction. N Engl. J Med 1993. 329, 1615 – 22.

ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction: ISIS-3. Lancet. 1992. 339, 753 – 770.

The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997. 337, 1118 – 23.

Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H and Chow A. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994. 91, 3670 – 74.

Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH and Berioli S. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial in farction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999. 137, 786 – 91.

Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L and White H. Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999. 354, 716 – 22

Martin U, Von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B and Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther. 1991. 50, 429 – 36.

GUSTO III Investigators. A comparison of reteplase for acute myocardial infarction. N Engl J Med. 1997. 337, 1118–23.

Gerheime B. Staphylococcal coagulation and fibrinolysis. Nature. 1948. 162, 732.

Lack CH. Staphylokinase: an activator of plasma protease. Nature. 1948. 161, 559.

Lewis JH and Ferguson JH. A proteolytic enzyme system of the blood. 111. Activation of dog serum profibrinolysin by staphylokinase. Am J Physiol. 1951. 166, 594 – 602.

Davidson F and Orma L. The activation of plasminogen by staphylokinase : comparison with streptokinase. Biochem. J. 1960. 76, 56 – 61.

Glanville Kitty L.A. A simple method of purifying staphylokinase. Biochem. J. 1963. 88, 11 – 14.

Jackson KW, Esmon N and Tang J: Streptokinase and staphylokinase. Methods Enzymol. 1981. 80, 387.

Kondo I, Itoh S and Takagi T. Purification of staphylokinase by affinity chromatography with human plasminogen, in Jeljaszewicz (ed): Staphylococci and Staphylococcal Infections. Zbl Bakt Suppl. 1981. 10, 343.

Sweet B, McNicol GP and Douglas AS. In vitro studies of staphylokinase. Clin Sci. 1965. 29, 375.

Lewis JH, Kerber CW and Wilson JH. Effects of fibrinolytic agents and heparin on intravascular clot lysis. Am J Physiol. 1964. 207, 1044 – 48.

Lewis JH and Shirakawa M. Effects of fibrinolytic agents and heparin on blood coagulation in dogs. Am J Physiol. 1964. 207, 1049 – 52.

Kanae K. Fibrinolysis by staphylokinase in vivo. Biol Abstr. 1986. 81:AB748 (abstr 65436)

KK Pulicherla, GS Gadupudi, VPB Rekha, K. Seetharam, Anmol Kumar, KRS Sambasiva Rao. Isolation, cloning and expression of mature staphylokinase from lysogenic Staphylococcus aureus collected from a local wound sample in a salt inducible E.coli expression host. International Journal of Advanced Science and Technology. 2011. 30, 35-42

Collen D, Silence K, Demarsin E, De Mol M and Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis. 1992. 6, 203 – 213.

Sako T, Sawaki S, Sakurai T, Ito S, Yoshizawa Y and Kondo I. Cloning and expression of the staphylokinase gene of Staphylococcus aureus in E. coli. Mol Gen Genet. 1983. 190, 271 – 77.

Behnke D and Gerlach D. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase – A bacterial plasminogen activator. Mol Gen Genet. 1987. 210, 528 – 34.

Hoylaerts M, Rijken DC, Lijnen HR and Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982. 257, 2912 – 19.

Collen D, Zhao ZA, Holvoet P and Marynen P. Primary structure and gene structure of staphylokinase. Fibrinolysis. 1992. 6, 226 – 31.

M.I.Bokarewa, T.Jin and Tarkowski A. Staphylococcus aureus: Staphylokinase. Int. J. Biochem. Cell Biol. 2006. 38, 504 – 09.

Jackson KW and Tang J. Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry. 1982. 21, 6620 – 25

Collen D and H.R. Lijnen. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?. Blood. 1994. 84, 680 – 686.

Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M and Lijnen HR. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem. 1993. 268, 8284 – 9.

McClintock DK and Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun. 1971. 43, 694 – 702.

Sakai M, Watanuki M and Matsuo O. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α2-plasmin inhibitor. Biochem Biophys Res Commun. 1989. 162, 830 – 7.

Lijnen HR, Van Hoef B, Matsuo O and Collen D. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochim Biophys Acta. 1992. 1118, 144 – 48.

Okada K, Yuasa H, Hagiya Y, Fukao H, Ueshima S and Matsuo O. Kinetic analysis of plasminogen activation by staphylokinase plasminogen complex in the presence of fibrin. Thromb Res. 1994. 76, 181 – 91.

Okada K, Nonaka T, Matsumoto H, Fukao H, Ueshima S and Matsuo O. Effects of α2-plasmin inhibitor on plasminogen activation by Staphylokinase plasminogen complex. Thromb Res. 1994. 76, 211 – 20.

Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S and Matsuo O. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem. 1991. 266, 11826 – 32.

Okada K, Ueshima S, Takaishi T, Yuasa H, Fukao H and Matauo O. Effects of fibrin and α2-antiplasmin an plasminogen activation by staphylokinase. Am J Hemat. 1996. 53, 151 – 57.

Vanderschueren S, Collen D and Van de Werf F. A pilot study on bolus administration of recombinant staphylokinasefor coronary artery thrombolysis. Thromb Haemost. 1996. 76, 541 – 44.

Armstrong PW, Burton JR, Palisatis D, Thompson CR, Van de Werf F, Rose B, Collen D and Teo KK. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). Am Heart J. 2000. 139, 820 – 23.

Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera M, Bode C, Adgey AA, Bar F, Vahanian A and Van de Werf F. CAPTORS II Investigators. Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS II). Am Heart J. 2003. 146, 484 – 88.

Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR and Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis. 1992. 6, 232 – 242.

Collen D and Vande Warf. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 1993. 87, 1850 – 53

Sakharov DV, Lijnen HR and Rijken DC. Interactions between Staphylokinase, Plasmin(ogen), and Fibrin. The journal of biological chemistry. 1996. 271, 27912 – 27918.

Sako T and Tsuchida N. Nucleotide sequence of the staphylokinase gene from Staphylococcus aureus. Nucleic Acids Res. 1983. 11, 7679 – 93.

Maria I. Bokarewa, Tao Jin and Andrej Tarkowski. Pathogens in focus. Staphylococcus aureus: Staphylokinase The International Journal of Biochemistry & Cell Biology. 2006. 38, 504 – 509.

Damaschun G, Damaschun H, Gast K, Misselwitz R, Zirwer D, Giihrs KH, Hartmann M, Schlott B, Triebel H and Behnke D. Physical and conformational properties of staphylokinase in solution. Biochim Biophys Acta. 1993. 1161, 244 – 248.

Jakub Kwiecinski, Elisabet Josefsson, Jennifer Mitchell, Judy Higgins, Mattias Magnusson, Timothy Foster, Tao Jin, and Maria Bokarewa. Activation of plasminogen by staphylokinase reduces the severity of Staphylococcus aureus systemic infection. The Journal of Infectious Diseases. 2010. 202, 1041 – 1049.

June-Hyung Kim, Sui-Lam Wong and Byung-Gee Kim. Optimization of Staphylokinase Production in Bacillus subtilis Using Inducible and Constitutive Promoters. Biotechnol. Bioprocess Eng. 2001. 6, 167 – 172.

Gerlach D, Kraft R and Behnke D. Purification and characterization of the bacterial plasminogen activator staphylokinase, secreted by a recombinant Bacillus subtilis. Zbl Bakt Mikr Hyg. 1988. 269, 314 – 322.

Schlott B, Hartmann M, Giihrs K-H, Birch-Hirschfeld E, Gase A, Vetterman S , Collen D and Lijnen HR. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine 26. Biochim Biophys Acta. 1994. 1204, 235 – 242.

Lee SJ, Kim C, Kim DM, Bae KH and Byun SM. High level secretion of recombinant staphylokinase into periplasm of Escherichia coli. Biotechnol. Lett. 1998. 20, 113 – 116.

Schlott B, Hartmann M, Gührs K, Birch-Hirschfeid E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D and Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology. 1994. 12, 185 – 189.

Nguyen and Quyen. Cloning, high-level expression, purification and characterization of a staphylokinase variant, SakɸC, from Staphylococcus aureus QT108 in Escherichia coli BL21. African Journal of Biotechnology. 2012. 11, 5995 – 6003

Schlott B, Gührs KH, Hartmann M, Röcker A and Collen D. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation. J. Biol. Chem. 1999. 272, 6067 – 6072.

Apte – Deshpnade A, Mandal G, Soorapaneni S, Prasad B, Kumar J and Padmanabhan S. High-level expression of non-glycosylated and active staphylokinase from Pichia pastoris. Biotechnol. Lett. 2009. 31, 811 – 817.

Mandi N, Soorapaneni S, Rewanwar S, Kotwal P, Prasad B, Mandal G and Padmanabhan S. High yielding recombinant staphylokinase in bacterial expression system: Cloning, expression, purification and activity studies. Protein Exp. Purif. 2009. 64, 69 – 75.

Manal Moussa, Mahmoud Ibrahim, Maria El Ghazaly, Jan Rohde, Stefan Gnoth, Andreas Anton, Frank Kensy and Frank Mueller. Expression of recombinant staphylokinase in the methylotrophic yeast Hansenula polymorpha. BMC Biotechnology. 2012. 12, 96.

Ren D, Li D, Yang W, Li Y, Gou X, Liang B, Li B and Wu Q. Novel preparation protocol for the expression and purification of recombinant staphylokinase. Biotechnol. Appl. Biochem. 2008. 51, 9 – 13.

Sako T. Overproduction of staphylokinase in Escherichia coli and its characterization. Eur. J. Biochem. 1985. 149, 557 – 563

Ye RQ, Kim JH, Kim BG, Szarka S, Sihota E and Wong SL. High-level secretory production of intact, biologically active staphylokinase from Bacillus subtilis. Biotechnol. Bioeng. 1999. 62, 87 – 96

Cheng Y, Li Y, Liu B and Guo L. Cloning and secretory expression of staphylokinase in Streptomyces lividans. Zhongguo Yi XueKeXue Yuan XueBao. 1998. 20, 428 – 432

Miele RG, Prorok M, Costa VA and Castellino FJ. Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity. J Biol Chem. 1999. 274, 7769 – 7776.

KK Pulicherla, K Seetharam, Anmol Kumar, VPB Rekha and KRS Sambasiva Rao. Cloning and high level expression of recombinant heterologous fusion protein SAK RGD in methanol inducible Pichia pastoris GS115. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2012. 3, 1008 – 1013.

Wei Mo, Yan-Ling Zhang, Hong-Shan Chen, Long-Sheng Wang, and Hou-Yan Song . A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition. J Thromb Thrombolysis. 2009. 28, 230 – 237

Seetha Ram Kotra, Anmol Kumar, KRS Sambasiva Rao and KK Pulicherla. Statistical Optimization of Media Components for Enhanced Production of the Recombinant Staphylokinase Variant from Salt Inducible E.Coli GJ1158. International Journal of Bio-Science and Bio-Technology. 2012. 4, 27 – 40.

Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT and Collen D. Comparative effect of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIb antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990. 16, 714 – 22

Yamada T, Shimada Y and Kikuchi M. Integrin-specific tissue type plasminogen activator engineered by introduction of the Arg-Gly-Asp sequence. Biochem Biophy Res Commun. 1996. 228, 306 – 11.

Szarka SJ, Sihota EG, Habibi HR and Wong SL. Staphylokinase as a plasminogen activator component in recombinant fusion proteins. Applied and Enviromental Microbiology 1999. 65, 506 – 13.

Lian Q, Szarka SJ, Kenneth KS and Wong SL. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clot. The J Biol Chem. 2003. 278, 26677 – 86.

Chen H, Mo W, Zhang Y, Su H, Ma J, Yao R, Zhang S, Ge J and Song H. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolyis and antiplatelet aggregation activities. European Journal of Pharmacology. 2007. 566, 137 – 44.

Van Zyl WB, Pretorius GHJ, Hartmann M and Kotze HF. Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. Thromb Res. 1997. 88, 419 – 26.

Szemraj J, Walkowiak B, Kawecka I, Janiszewska, Buczko W, Bartkowiak J and Chabielska E. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity-a staphylokinase variant in vitro study. Thromb Haemost. 2005. 3, 2156 – 65.

Kowalski M, Brown G, Bieniasz M, Oszajca K, Chabielska E, Pietras T, Szemraj Z, Ola EM, Bartkowiak J and Szemraj J. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent — a staphylokinase variant. Acta Biochimica Polonica. 2009. 1, 41 – 53.

How to Cite
Kotra, S. R., J, P. B., Kumar, A., Rao, krs S., & Pulicherla, K. K. (2013). STAPHYLOKINASE: A BOON IN MEDICAL SCIENCES – REVIEW. Mintage Journal of Pharmaceutical and Medical Sciences (ISSN: 2320-3315), 28-34. Retrieved from

Most read articles by the same author(s)